Dysgerminoma of the ovary in a patient with triple-X syndrome (47, XXX) and Marfanoid habitus features

Authors: Karolina Moskwinska, Marcin Sniadecki, Dariusz Wydra

DOI: 10.5603/GP.a2021.0106
Article type: Clinical vignette
Submitted: 2021-02-23
Accepted: 2021-03-24
Published online: 2021-05-20

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Articles in "Ginekologia Polska" are listed in PubMed.
Dysgerminoma of the ovary in a patient with triple-X syndrome (47, XXX) and Marfanoid habitus features

Karolina Moskwinska, Marcin Sniadecki, Dariusz Wydra

Department of Gynecology, Gynecologic Oncology and Gynecologic Endocrinology, Medical University of Gdansk, Poland

Corresponding author:
Karolina Moskwinska
Department of Gynecology, Gynecologic Oncology and Gynecologic Endocrinology, Medical University of Gdansk, Poland
e-mail: k.moskwinska@gmail.com

Key words: dysgerminoma; triple-X syndrome; Shprintzen-Goldberg syndrome; Marfan syndrome

INTRODUCTION

Dysgerminoma is a malignant ovarian tumor beginning in premeiotic germ cells, with clinically aggressive behavior and good prognosis. Triple-X syndrome is characterized by an extra X chromosome due to a random error during cell division in sperm or egg formation and is not typically an inherited condition. Premature ovarian failure or ovarian abnormalities are sometimes found coincidentally. Associations between triple X syndrome and dysgerminoma have never been investigated.

CASE REPORT

A 22-year-old woman with Marfanoid habitus and an ovarian dysgerminoma (Fig. 1) was admitted to the Department of Gynecology. The patient’s medical history showed borderline intellectual disability and clinical suspicion of Marfan syndrome (MFS) (Fig. 2) Surgical treatment was performed, and post-surgery, four cycles of bleomycin, etoposide, cisplatin (BEP) chemotherapy. She is alive and well with no signs of recurrence 10 years after the completion of treatment.

MATERIAL AND METHODS
Cytogenetic studies were performed using conventional GTG–banding of lymphocyte metaphase chromosomes at a 550-band level. DNA was isolated from the peripheral blood leukocytes of the patient and of nine anonymous healthy female volunteers (reference control DNA). Array Comparative Genomic Hybridization (aCGH) analysis was performed. Genomic imbalances identified were verified in the Database of Genomic Variants (DGV; http://projects.tcag.ca/variation; last accessed December 2020). We searched ECARUCA [1], Decipher [2] and Medline/OMIM [3] for instances of patients with constitutional chromosomal aberrations at chromosome 4q26.

RESULTS

The patient was diagnosed with triple-X syndrome by karyotyping: 47, XXX. Further aCGH analysis confirmed the chromosome analysis and identified interstitial deletion of about 1.1Mb at chromosome 4q26.

Following the revised Ghent Marfan Syndrome Diagnostic Criteria (2010) [4], the patient having only skeletal features but no signs of other organ systems’ involvement, and a negative mutation evaluation of the FBN1 gene, diagnosis excluded MFS. Differential diagnosis identified Shprintzen-Goldberg syndrome [5] as the most likely alternative diagnosis.

DISCUSSION

Genetic studies confirmed diagnosis of the triple-X syndrome and revealed a novel interstitial deletion at chromosome 4q26. The deletion spanned 1.1Mb, comprised of one gene protein coding: translocation associated membrane protein 1 like 1 (TRAM1L1) of unknown function.

The OMIM database provided no information on this gene mutation [3], nor is such reported in the Developmental Disorders Genotype-Phenotype Database [2]. The decipher haploinsufficiency score (HI index) was estimated as 85%, and accordingly, the gene is unlikely to exhibit haploinsufficiency [2]. The adjacent genomic regions were not found to be enriched in low copy repeat sequences or segmental duplications, nor possessing significant enhancer/silencer or promotor-associated histone marks (www.genome.ucsc.edu). Therefore, it seems unlikely that the novel 4q26 deletion was responsible for the clinical features observed in the patient.

Among individuals with chromosome aberrations, a higher risk of germinal tumors has been found in cases of 45,X/46,XY mosaicism, resulting in active oncological prophylaxis in
these patients. Associations between triple-X syndrome and ovarian tumors have been rarely documented. Ovarian tumors have not been clinically linked to Shprintzen-Goldberg syndrome so far. However, further research on the cooccurrence of germ cell tumors and chromosomal abnormalities is necessary to identify risk factors of these relatively rare neoplasms.

Acknowledgements
This study used data generated by the DECIPHER community. A list of centres contributing to the data generation is available from https://decipher.sanger.ac.uk/about/stats and via email from decipher@sanger.ac.uk. DECIPHER project funding was provided by Wellcome. The authors would like to thank Beata Lipska-Ziętkiewicz and Magdalena Koczkowska (Department of Biology and Medical Genetics, Medical University of Gdańsk) for their help in writing the manuscript.

Conflicts of interest
The authors declare no conflict of interest.

REFERENCES
Figure 1. Dysgerminoma. Uniform tumor cells surrounded by connective tissue stroma infiltrated by lymphocytes (H&E, ×20)
Figure 2. Clinical features of Marfanoid habitus (dolichocephaly, micrognathia, pectus carinatum, elongated extremities)